EGRX (Eagle Pharmaceuticals) Total Stockholders Equity: $252.0 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EGRX Eagle Pharmaceuticals Inc EGRX
16 GF Score
Price $0.76
View Full Analysis

What is Eagle Pharmaceuticals Total Stockholders Equity?

Eagle Pharmaceuticals EGRX +0.67% 16 Total Stockholders Equity is $252.0 Mil as of Jun. 2023. GuruFocus rates EGRX with a GF Score™ of 16/100.

Eagle Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $252.0 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Eagle Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2023 was $19.16. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Eagle Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2023 was 0.28.

Eagle Pharmaceuticals  (OTCPK:EGRX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Eagle Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(252.04-0)/13.155
=19.16

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Eagle Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(9.719 + 61.896) / 252.04
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eagle Pharmaceuticals Total Stockholders Equity Related Terms

Eagle Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Eagle Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eagle Pharmaceuticals Total Stockholders Equity Chart

Eagle Pharmaceuticals Annual Data
Trend Sep13 Sep14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 160.76 179.17 186.01 176.45 233.56

Eagle Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 237.98 231.78 233.56 242.85 252.04
EGRX
16GF Score
Eagle Pharmaceuticals Inc EGRX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $252.0 Mil mean?
Eagle Pharmaceuticals (EGRX) has a Total Stockholders Equity of $252.0 Mil as of Jun. 2023. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Eagle Pharmaceuticals and its competitors.
Is Eagle Pharmaceuticals' Total Stockholders Equity too high?
Eagle Pharmaceuticals' current Total Stockholders Equity is $252.0 Mil. Overall, Eagle Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Eagle Pharmaceuticals' Total Stockholders Equity compare to IXHL and RMTI?
Eagle Pharmaceuticals' Total Stockholders Equity of $252.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Eagle Pharmaceuticals and its competitors. Eagle Pharmaceuticals's current Total Stockholders Equity is $252.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eagle Pharmaceuticals stock overvalued right now?
Eagle Pharmaceuticals (EGRX) has a current Total Stockholders Equity of $252.0 Mil. The current Total Stockholders Equity is $252.0 Mil. Eagle Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Eagle Pharmaceuticals (EGRX), the current Total Stockholders Equity is $252.0 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eagle Pharmaceuticals Business Description

Address 50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advance stages of development and is under review for approval by the Food and Drug Administration.
16GF Score

Get the complete analysis for EGRX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price